Study Summary
This trial is studying a new drug to treat early Alzheimer's. It's a carefully designed, safe study to see if it works.
- Early-Onset Alzheimer's Disease
- Alzheimer's Disease
Treatment Effectiveness
Study Objectives
2 Primary · 15 Secondary · Reporting Duration: 160 weeks
Trial Safety
Trial Design
2 Treatment Groups
Group A - Active Comparator
1 of 2
Group B - Placebo Comparator
1 of 2
Active Control
Non-Treatment Group
800 Total Participants · 2 Treatment Groups
Primary Treatment: Group A - Active Comparator · Has Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 55 - 80 · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Is participation in this experiment open to individuals over forty years of age?
"The age requirements for this clinical trial are between 55 and 80 years old, as per the guidelines outlined in the inclusion criteria." - Anonymous Online Contributor
Who would be a suitable candidate to enroll in this clinical research project?
"To be admitted to this clinical trial, potential enrollees must have been diagnosed with Alzheimer's disease and are between the ages of 55-80. Approximately 800 people will need to participate in order for the results to be valid." - Anonymous Online Contributor
What potential hazards exist for individuals taking Group A - Active Comparator?
"Our experts at Power have rated Group A - Active Comparator's safety as a 3 due to the abundance of clinical evidence indicating efficacy and multiple instances validating its security." - Anonymous Online Contributor
Is this research endeavor currently seeking participants?
"Affirmative. The clinicaltrials.gov database shows that this investigation is recruiting participants, having been first posted on December 1st 2022 and most recently updated on the 19th of December 2022. It aims to recruit 800 patients from one location." - Anonymous Online Contributor
How many individuals have been accepted for this clinical trial thus far?
"Affirmative. According to clinicaltrials.gov, this medical trial is currently in the process of recruitment and was initially published on December 1st 2022 with its most recent updates being posted on December 19th 2022. 800 candidates are needed for participation from one site." - Anonymous Online Contributor
What is the aim of this research endeavor?
"This research project will evaluate the primary outcome, Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB), for a period of 1 year. Secondary endpoints include alterations in Alzheimer's Disease Assessment Scale, cognitive subscale (ADAS-Cog 13); Amsterdam Instrumental Activities of Daily Living Questionnaire Short Version (A-IADLQSV); and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)." - Anonymous Online Contributor